Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel

Introduction: Conventional anti-androgen regimens were widely used as an initiation or combined androgen blockade (CAB) therapy in advanced prostate cancer patients. Currently, new androgen pathway inhibitors such as abiraterone acetate (AA) and enzalutamide had been proven effective in metastatic c...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Pharmacol
Päätekijät: Li, Jian-Ri, Chiu, Kun-Yuan, Wang, Shian-Shiang, Yang, Cheng-Kuang, Chen, Chuan-Shu, Ho, Hao-Chung, Hung, Chi-Feng, Cheng, Chen-Li, Yang, Chi-Rei, Chen, Cheng-Che, Wang, Shu-Chi, Lin, Chia-Yen, Chang, Chao-Hsiang, Hsu, Chiann-Yi, Ou, Yen-Chuan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2017
Aiheet:
Pharmacology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5702804/
https://ncbi.nlm.nih.gov/pubmed/29213237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00836
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia